Demographics and baseline characteristics
| Parameter* | Adalimumab+MTX (n=171) | MTX (n=163) |
|---|---|---|
| Age±SD (year) | 54.0±13.1 | 54.0±13.2 |
| Females (n (%)) | 144 (84.2) | 128 (78.5) |
| RA duration±SD (year) | 0.3±0.4 | 0.3±0.4 |
| Weight±SD (kg) | 54.4±9.7 | 56.1±12.3 |
| Previous DMARD use (n (%)) | 74 (43.3) | 87 (53.4) |
| 1 DMARD | 57 (33.3) | 69 (42.3) |
| 2 DMARDs | 17 (9.9) | 18 (11.0) |
| Corticosteroid use at baseline (n (%)) | 58 (33.9) | 49 (30.1) |
| RF positive (n (%)) | 146 (85.4) | 136 (83.4) |
| Mean titre±SD (IU/ml) | 154.5±202.3 | 163.7±362.8 |
| Anti-CCP positive (n (%)) | 145 (84.8) | 136 (83.4) |
| Mean titre±SD (U/ml) | 386.2±694.2 | 241.3±367.2 |
| ESR (mm/h) | 59.9±30.1 | 61.8±29.0 |
| CRP (mg/dl) | 2.9±3.0 | 3.1±3.3 |
| Swollen joint count (n±SD) | ||
| 0–28 | 11.5±4.7 | 11.8±5.3 |
| 0–66 | 16.5±6.2 | 17.3±7.7 |
| Tender joint count (n±SD) | ||
| 0–28 | 13.2±5.8 | 13.2±6.1 |
| 0–68 | 20.7±9.4 | 21.1±10.2 |
| mTSS | 13.6±22.3 | 13.6±17.4 |
| Erosion score | 7.5±11.6 | 7.3±9.2 |
| Joint space narrowing score | 6.2±11.4 | 6.2±9.4 |
| DAS28-ESR | 6.6±0.9 | 6.6±1.0 |
| DAS28-CRP | 5.8±1.0 | 5.9±1.0 |
| HAQ-DI score | 1.1±0.7 | 1.3±0.8 |
| SDAI score | 40.7±12.0 | 41.4±13.8 |
| CDAI score | 37.8±10.9 | 38.3±12.4 |
| Physician's global assessment of disease activity±SD (mm) | 65.8±18.4 | 66.2±18.8 |
| Patient's global assessment of disease activity±SD (mm) | 64.1±24.8 | 66.4±23.7 |
*Data are mean±SD unless otherwise indicated.
CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.